![]() | |
公司名 | BOC Sciences |
联系人 | Linna Green |
电 话 | +16314854226 |
手 机 | +16314854226 |
电子邮件 | info@bocsci.com |
网 址 | https://www.bocsci.com/ |
地 区 | 其他 |
邮 编 | 11967 |
在线询盘仅适合非紧急采购的情形,您需要留下收货地域,采购数量及联系方式。供应商在收到您的询盘信息后,会通过您留下的联系方式联络您。如果您希望立即和供应商交谈,请直接拨打供应商电话。供应商手机:+16314854226
中文名 | Olmutinib |
英文名 | Olmutinib |
别名 | 奥莫替尼;HM61713(奥莫替尼);表皮生长因子受体酪氨酸激酶抑制剂;N-(3-((2-((4-(4-甲基哌嗪-1-基)苯基)氨基)噻吩并[3,2-D]嘧啶-4-基)氧基)苯基)丙烯酰胺;N-[3-[[2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氧基]苯基]-2-丙烯酰胺 |
CAS | 1353550-13-6 |
EINECS | |
化学式 | C26H26N6O2S |
分子量 | 486.59 |
inchi | |
包装信息 | 200 mg |
价格 | $199 |
产品描述 | Olmutinib Olmutinib, also called as HM61713 and BI-1482694, is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed for treatment of advanced and metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC). In May 2016, olmutinib received its first global approval in South Korea for the treatment of EGFR T790M mutation-positive lung cancer. Olmutinib is also a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK). |
产品链接 | https://www.bocsci.com/olmutinib-cas-1353550-13-6-item-470842.html |
更新日期 | 2025-04-30 11:27:47 |